Microgenics keeps technology in management buy-out
This article was originally published in Clinica
Executive Summary
Microgenics is buying itself out of Roche Boehringer Mannheim, taking with it the intellectual property rights to the technology it developed before the company was sold, first to Boehringer, and subsequently, in the Boehringer deal, to Roche.